12.40MMarket Cap-572P/E (TTM)
1.220High1.060Low131.35KVolume1.220Open1.200Pre Close149.54KTurnover1.85%Turnover RatioLossP/E (Static)10.69MShares6.41052wk High0.65P/B8.24MFloat Cap0.84052wk Low--Dividend TTM7.10MShs Float22.000Historical High--Div YieldTTM13.33%Amplitude0.840Historical Low1.138Avg Price1Lot Size
Bionomics Stock Forum
BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments.
Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's...
5 MINUTES AGO, 6:00 AM EDT
VIA GLOBENEWSWIRE
Continued strengthening BNC210 intellectual property portfolio in the U.S. and abroad.
Future Anticipated Milestones for BNC210 Clinical Program
Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.
The Company plans to discuss a potential dose-ranging late-stage study of BNC210 in PTSD with the FDA; an update on the next st...
No comment yet